Thermal therapy in the treatment of benign prostatic hyperplasia

Current Opinion in Urology

Volumn 7, Issue 1, 1997, Pages 15-20

  Bernier, Pablo A ^a   Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; HYPERTHERMIC THERAPY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYMPTOM; URODYNAMICS;

EID: 0031055954     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199701000-00004     Document Type: Article

References (30)

1. Abbou CC, Colombel M, Payan C, Beurton D, Viens-Bitker C, Richard F, Gibod LB, Leduc A, Jardin A, Chatelain C et al.: The efficacy of microwave induced hyperthermia in the treatment of BPH: the Paris public hospitals' experience. Prog Clin Biol Res 1994, 386:449-453.
2. Madersbacher S, Kratzik C, Susani M, Marberger M: Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol 1994, 152:1956-1960.
3. Bihrle R, Foster RS, Sanghvi NT, Donohue JP, Hood PJ: High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. J Urol 1994, 151:1271-1275.
4. Oesterling JE, Issa MM, Roehrborn CG, Perez-Marrero R, Bruskewitz R, Naslund MJ, Shumaker BP: A single blind, prospective, randomized clinical trial comparing transurethral needle ablation (TUNA) to transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH) [Abstract]. J Urol 1996, 155:403A.
5. Blute ML: Transurethral microwave thermotherapy: refining treatment strategy for benign prostatic hyperplasia. Curr Opin Urol 1996, 6:14-19. Latest review on the subject in this series.
6. Blute ML, Patterson DE, Segura JW, Hellerstein DK, Tomera KM: Transurethral microwave thermotherapy versus sham: a prospective double-blind randomized study [Abstract]. J Urol 1994, 151: 415A.
7. Ogden CW, Reddy P, Johnson H, Ramsay JW, Carter SS: Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993, 341:14-17.
8. de la Rosette JJ, de Wildt MJ, Alivizatos G, Froeling FM, Debruyne FM: Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994, 44:58-63.
9. de Wildt MJAM, Hubregtse M, Ogden C, Carter SSC, Debruyne FMJ, de la Rosette JJMCH: A 12-month study of the placebo effect in transurethral microwave thermotherapy. Br J Urol 1996, 77:221-227. A randomized, controlled trial.
10. Bdesha AS, Bunce CJ, Snell ME, Witherow RO: A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. J Urol 1994, 152:453-458.
11. Dahlstrand C, Walden M, Geirsson G, Pettersson S: Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 1995, 76:614-618. A randomized, controlled trial comparing TUMT with sham treatment or TURP.
12. Dahlstrand C, Walden M, Petterson S: Three-year follow-up of transurethral microwave thermotherapy versus transurethral resection for benign prostatic obstruction [Abstract]. J Urol 1996, 153:434A.
13. •] examine whether noninvasive parameters such as symptoms, flow rate, and prostate size can predict the outcome of TUMT therapy.
14. •] examine whether noninvasive parameters such as symptoms, flow rate, and prostate size can predict the outcome of TUMT therapy.
15. ••] examine the predictive value of invasive pressure-flow studies regarding clinical outcomes in patients treated with TUMT.
16. ••] examine the predictive value of invasive pressure-flow studies regarding clinical outcomes in patients treated with TUMT.
17. Shapiro E, Becich MJ, Hartanto V, Lepor H: The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992, 147:1293-1297.
18. Devonec M, Berger N, Fendler JP, Joubert P, Nasser M, Perrin P: Thermoregulation during transurethral microwave thermotherapy: experimental and clinical fundamentals. Eur Urol 1993, 23(suppl 1):63-67.
19. Park YC, Hashimoto K, Ohnishi N, Esa A, Sugiyama T, Kurita T, Katoh Y, Miyatake R, Kiwamoto H: How does thermotherapy effectively work on benign prostatic hyperplasia - an experimental study. Nippon Hinyokika Gakkai Zasshi 1995, 86:1360-1367.
20. Arai Y, Fukuzawa S, Terai A, Yoshida O: Transurethral microwave thermotherapy for benign prostatic hyperplasia: relation between clinical response and prostate histology. Prostate 1994, 28:84-88.
21. Berg C, Choi N, Colombeau P, Debruyne F, Hallin A, Perrin P, Van Couwelart R: Responders versus non-responders to thermotherapy in BPH: a multicenter retrospective analysis of patient and treatment profiles [Abstract]. J Urol 1993, 149:251A.
22. Devonec M, Ogden C, Perrin P, St Clair Carter S: Clinical response to transurethral microwave thermotherapy is thermal dose dependent. Eur Urol 1993, 23:267-274.
23. Goldfarb B, Bartkiw T, Trachtenberg J: Microwave therapy of benign prostatic hyperplasia. Urol Clin North Am 1995, 22:431-439.
24. •] examine ways to monitor blood flow in the prostate, document the blood flow changes seen during TUMT, and show how these changes affect the efficacy of TUMT.
25. •] examine ways to monitor blood flow in the prostate, document the blood flow changes seen during TUMT, and show how these changes affect the efficacy of TUMT.
26. Devonec M, Tomera K, Perrin P: Review: transurethral microwave thermotherapy in benign prostatic hyperplasia. J Endourol 1993, 7:255-259.
27. •] examine the effect of higher energy delivery on the clinical outcomes after TUMT.
28. •] examine the effect of higher energy delivery on the clinical outcomes after TUMT.
29. •] examine the effect of higher energy delivery on the clinical outcomes after TUMT.
30. Ramsey EW, Miller PD, Parsons K: Preferential heating using transurethral thermoablation (T3) improves clinical results [Abstract]. J Urol 1996, 153:402. First report of the T3, a second generation TUMT delivery device, in a prospective study.